Sanofi购买英国生物技术副生物,价值高达16亿美元,用于推进呼吸系统病毒疫苗。 Sanofi buys UK biotech Vicebio for up to $1.6 billion to advance respiratory virus vaccines.

法国一家制药公司Sanofi同意以11.5亿美元购买英国生物技术公司Vitbio公司,可能达到4.5亿美元的里程碑付款额。 Sanofi, a French pharmaceutical company, has agreed to acquire UK biotech firm Vicebio for $1.15 billion, with potential milestone payments up to $450 million. 购置的目的是扩大Sanofi的呼吸道疫苗,包括一个呼吸道同步病毒和人类甲型肺炎病毒的候选者。 The acquisition aims to expand Sanofi's respiratory vaccines, including a candidate for respiratory syncytial virus and human metapneumovirus. 维比奥的“分子Clamp”技术将有助于更快地研制疫苗,并在标准的制冷温度下更容易地储存。 Vicebio's 'Molecular Clamp' technology will help in faster vaccine development and easier storage at standard refrigeration temperatures. 这笔交易预计将在年底前结束,不会对Sanofi的2025年财务指南产生重大影响。 The deal is expected to close by the end of the year and won't significantly impact Sanofi's 2025 financial guidance.